Filtered By:
Specialty: Allergy & Immunology
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 631 results found since Jan 2013.
Single-cell analysis of the miRNA activities in tuberculous meningitis (TBM) model mice injected with the BCG vaccine
CONCLUSION: In our study, an in-depth exploration of the mRNA expression and miRNA activity of macrophages, microglia, epididymal cells, neurons and vascular smooth muscle cells during TBM progression was conducted using scRNA-Seq, which provided novel insights into the immune cell engagement in TBM patients.PMID:37708706 | DOI:10.1016/j.intimp.2023.110871
Source: International Immunopharmacology - September 14, 2023 Category: Allergy & Immunology Authors: Xiaolin Zhang Lei Pan Peng Zhang Lei Wang Yidan Shen Ping Xu Yang Ren Wei Huang Ping Liu Qingguo Wu Feng Li Source Type: research
Antibodies against Neisseria meningitidis serogroups A, C, W and Y in serum and saliva of Norwegian adolescents
CONCLUSION: Unvaccinated adolescents in Norway have a low degree of natural immunity against the serogroups of N. meningitidis predominating among cases of IMD in this age group. Therefore, introduction of MCV4 for adolescents in the NIP is recommended.PMID:37648606 | DOI:10.1016/j.vaccine.2023.08.052
Source: Vaccine - August 30, 2023 Category: Allergy & Immunology Authors: Sara Viksmoen Watle Bente B ørud Ida Laake Marta Baranowska-Hustad Diane Bryant-Bratlie Terese Bekkevold Dominique A Caugant Gro Tunheim Lisbeth Meyer N æss Source Type: research
Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" Vaccine 41(1) (2023) 85-91
Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.07.039. Online ahead of print.NO ABSTRACTPMID:37625991 | DOI:10.1016/j.vaccine.2023.07.039
Source: Vaccine - August 25, 2023 Category: Allergy & Immunology Authors: Nusrat Homaira Roxanne Strachan Helen Quinn Sean Beggs Mejbah Bhuiyan Asha Bowen Laura K Fawcett Gwendolyn L Gilbert Stephen B Lambert Kristine Macartney Helen S Marshall Andrew C Martin Gabrielle McCallum Angela McCullagh Tim McDonald Hiran Selvadurai Pe Source Type: research
Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study
CONCLUSIONS: PCV13 vaccination among children aged 0-5 years substantially reduced the incidence of all-cause pneumonia. Direct immunization of children under 5 years is an effective strategy to combat outpatient pneumonia, and hospitalized pneumonia.PMID:37620204 | DOI:10.1016/j.vaccine.2023.08.041
Source: Vaccine - August 24, 2023 Category: Allergy & Immunology Authors: Jie Tian Bo Zheng Laibao Yang Ying Guan Chunze Xu Weibing Wang Source Type: research
Individual polysaccharide quantification in polyvalent pneumococcal conjugate vaccine using rate nephelometry
J Immunol Methods. 2023 Aug 16:113539. doi: 10.1016/j.jim.2023.113539. Online ahead of print.ABSTRACTThe multivalent pneumococcal conjugate vaccine (PCV) contains purified polysaccharides of different serotypes conjugated to a carrier protein. Testing the final formulated product for individual serotype polysaccharide content is critical in vaccine quality control which requires an assay specific to each serotype polysaccharide present in the formulated product. Antibodies specific to the serotypes specific polysaccharide were used in rate nephelometry assay for quantifying individual serotype polysaccharides in the formul...
Source: Journal of Immunological Methods - August 18, 2023 Category: Allergy & Immunology Authors: Burki Rajendar Jaya Sheela Pydigummala Ganti Sreenivasa Rao Ramakrishna Chigurambotla Ramesh V Matur Source Type: research
Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies
CONCLUSIONS: Vaccinating older adults with higher-valency PCVs, especially PCV20, could substantially reduce the remaining IPD burden in high-income countries, regardless of current PCV use in pediatric NIPs and adult PPSV23 policies.PMID:37544825 | DOI:10.1016/j.vaccine.2023.08.001
Source: Vaccine - August 6, 2023 Category: Allergy & Immunology Authors: Lindsay R Grant Mary P E Slack Christian Theilacker Jelena Vojicic St éphane Dion Ralf-Rene Reinert Luis Jodar Bradford D Gessner Source Type: research
Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines
Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.07.054. Online ahead of print.ABSTRACTFor the batch release of vaccines, potency release assays are required. Non-animal in vitro tests have numerous advantages and are preferred; however, several vaccines are still released using in vivo assays. Their major drawback is the inherent variability with its practical implications. We quantified the variability of in vivo potency release assays for whole-cell pertussis, inactivated polio and meningococcal B (MenB) vaccines which showed large CV (Coefficient of Variation) ranging from 34% to 125%. As inheren...
Source: Vaccine - August 1, 2023 Category: Allergy & Immunology Authors: Cerissa van Walstijn Stefan Verweij Rory Care Peter Rigsby Eli-Boaz Clapper Kevin Markey Rob J Vandebriel Paul Stickings Marcel H N Hoefnagel Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
